Skip Navigation

News & Resources

Subscribe to NHLBI Press Releases
July 1, 2015

NHLBI Media Availability: Largest Study of Gene Mutations in Aplastic Anemia May Help Optimize Treatment

Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. It is the largest study of its kind to examine gene mutations in aplastic anemia, the scientists note.

June 19, 2015

NHLBI Media Availability: Scientists develop method of producing large quantities of selectively labeled RNA molecules

Study opens door to new opportunities in medicine and research

WHAT: Scientists have developed an efficient method of producing substantial quantities of RNA molecules with selectively labeled regions, paving the way for more advanced research and medical applications. RNA — DNA's lesser-known partner molecule — plays a significant role not only in genetic activities but in many other biological functions like enzymatic processes. It also is an important research, medical diagnostic, and therapeutic tool.

Subscribe to NHLBI In The News
July 1, 2015 : MedPage Today
Neal S Young M.D.

Prognosis and treatment for aplastic anemia require tailoring based on which mutations patients have among a handful of leukemia-related genes, according to a new study from researchers including NHLBI's Dr. Neal S. Young.

June 29, 2015 : The Diane Rehm Show
Toren Finkel M.D., Ph.D.

NHLBI's Dr. Toren Finkel joined a live radio panel discussion on the Diane Rehm Show to discuss his anti-aging research involving work on mice. Other panel members included National Institute on Aging's Dr. Mark Mattson and Massachusetts Institute of Technology's Leonard Guarente.

August 20, 2015
Natcher Conference Center (NIH Campus) 45 Center Drive Bethesda, MD 20892
The NHLBI Annual Sickle Cell Disease Clinical Trials Meetings provide a yearly forum for investigators, practitioners, and interested health care providers to discuss the progress of ongoing clinical trials, hear presentations about new developments in scientific and clinical aspects of SCD, and interact with other investigators and NHLBI Program Staff. This year, the meeting will begin on August 18, 2015 and end on August 20, 2015. Scheduled presentations include a two-part symposium on basic and clinical aspects of sickle cell pain, a symposium on the current status of hematopoietic stem cell transplantation in SCD, and a session focusing on using Patient Reported Outcomes in clinical SCD research. This meeting is an opportunity to meet and exchange ideas with diverse group of SCD investigators and providers, as well as NIH Program Officers in an informal setting.
September 29, 2015 to September 30, 2015
Natcher Conference Center (Building 45), National Institutes of Health, Bethesda, Maryland
The event will bring together experts in stem cell biology, cardiovascular development, translating stem cell biology, cardiac remodelling and inflammation, vascular remodelling and inflammation, and tissue engineering/genome editing/new technologies. The emphasis will be on recent discoveries and trends. We will examine the challenges and critical questions that require answers as the field moves forward to clinical applications. The Symposium’s goals are to help the science and field move forward, to find consensus regarding the translation of stem cell biology and research into a clinical setting, and to inspire participants in their own work.